STOCK TITAN

Ionis Pharmaceuticals (NASDAQ: IONS) director sells shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals director Allene M. Diaz exercised stock options and then sold the resulting shares. On July 7, 2026, Diaz exercised a non-qualified stock option to acquire 10,111 shares of common stock at $47.11 per share, then sold 10,111 shares in open-market transactions at a weighted average price of $85.4156 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Diaz directly owned 3,811 shares of Ionis common stock.

Positive

  • None.

Negative

  • None.
Insider Diaz Allene M.
Role Director
Sold 10,111 shs ($864K)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 10,111 $0.00 --
Exercise Common Stock 10,111 $47.11 $476K
Sale Common Stock 10,111 $85.4156 $864K
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct); Common Stock — 13,922 shares (Direct)
Footnotes (1)
  1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Shares sold 10,111 shares Common Stock open-market sale on July 7, 2026 at weighted average $85.4156
Sale price range $85.040–$85.730 per share Price range for multiple sale transactions on July 7, 2026
Options exercised 10,111 shares Non-Qualified Stock Option exercised into common stock on July 7, 2026
Option exercise price $47.11 per share Exercise price of Non-Qualified Stock Option
Shares held after transaction 3,811 shares Common Stock directly owned by Diaz after the reported trades
Rule 10b5-1 plan adoption date November 25, 2025 Date Diaz adopted the trading plan used for these sales
Rule 10b5-1 Trading Plan regulatory
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of $47.1100 per share."
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average price financial
"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Ionis (IONS) director Allene M. Diaz report in this Form 4?

Allene M. Diaz reported exercising a stock option for 10,111 Ionis shares and then selling 10,111 shares in the open market. These trades were executed under a pre-arranged Rule 10b5-1 trading plan on July 7, 2026.

How many Ionis (IONS) shares did the director sell and at what price?

Diaz sold 10,111 shares of Ionis common stock at a weighted average price of $85.4156 per share. The sales occurred in multiple trades within a price range from $85.040 to $85.730 per share, as disclosed in the Form 4 footnote.

What stock options did the Ionis (IONS) director exercise in this filing?

Diaz exercised a non-qualified stock option covering 10,111 shares of Ionis common stock at an exercise price of $47.11 per share. Following the exercise, the option position reported in this filing was fully used, with zero derivative shares remaining.

How many Ionis (IONS) shares does Allene M. Diaz hold after these transactions?

After the reported option exercise and share sale, Diaz directly holds 3,811 shares of Ionis common stock. This post-transaction share balance reflects the net position remaining following the sale of 10,111 shares on July 7, 2026.

Were the Ionis (IONS) share sales by the director made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Diaz on November 25, 2025. Such plans pre-schedule trades, reducing the role of day-to-day discretion in the timing of sales.

What is the price range of Ionis (IONS) trades disclosed in this Form 4?

The filing reports that the 10,111 shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 per share. The reported $85.4156 figure is a weighted average across these individual trades.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Diaz Allene M.

(Last)(First)(Middle)
2855 GAZELLE COURT

(Street)
CARLSBAD CALIFORNIA 92010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/07/2026M10,111A$47.1113,922D
Common Stock07/07/2026S10,111(1)D$85.4156(2)3,811D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$47.1107/07/2026M10,11107/01/202506/30/2034Common Stock10,111$0.00D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
By: Patrick R. O'Neil, attorney-in-fact For: Allene M. Diaz07/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)